- Home
- RMR vs ALDX Comparison
RMR vs ALDX Comparison
Compare RMR & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMR | ALDX |
|---|---|---|
| Founded | 1986 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.2M | 89.3M |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RMR | ALDX |
|---|---|---|
| Price | $19.46 | $1.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $19.00 | $5.50 |
| AVG Volume (30 Days) | 86.9K | ★ 660.9K |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | ★ 10.37% | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $700,284,000.00 | N/A |
| Revenue This Year | $259.61 | N/A |
| Revenue Next Year | $2.45 | N/A |
| P/E Ratio | $20.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.27 | $1.07 |
| 52 Week High | $21.45 | $5.93 |
Technical Indicators
Market Signals| Indicator | RMR | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 45.02 | 46.93 |
| Support Level | $18.90 | $1.47 |
| Resistance Level | $20.52 | $1.60 |
| Average True Range (ATR) | 0.37 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 24.50 | 48.28 |
Price Performance
Historical ComparisonAbout RMR The RMR Group Inc.
The RMR Group Inc is a U.S. based real estate investment manager engaged in commercial real estate, private capital, and credit strategies. Its portfolio covers various commercial real estate asset classes, and it manages investments across various industries, geographies and asset classes.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.